Subtopic Deep Dive

Clinical Pharmacokinetics in Practice
Research Guide

What is Clinical Pharmacokinetics in Practice?

Clinical Pharmacokinetics in Practice applies pharmacokinetic principles to individualize drug dosing, implement therapeutic drug monitoring, and adjust doses for diverse patient populations including geriatrics and those on polypharmacy.

This subtopic emphasizes clinical pharmacist interventions to prevent drug-related problems from pharmacokinetic alterations in vulnerable groups. Key studies document error rates exceeding 20% in HIV and antineoplastic therapies (Kohler et al., 2002; Carcelero et al., 2011). Over 500 papers address dosing optimization, with foundational guidelines cited 120+ times.

Curated Papers

Key Challenges

Why It Matters

Clinical pharmacokinetics guides dose adjustments in geriatrics, reducing adverse events from polypharmacy as shown in Hailu et al. (2020) where pharmacist interventions cut drug-related problems by 30% in admitted patients. In HIV care, Carcelero et al. (2011) reported pharmacists resolving 25% error rates from dose and interaction issues, improving outcomes. Antineoplastic guidelines by Kohler et al. (2002) prevent medication errors, saving costs in oncology; Luo et al. (2017) demonstrated 40% reduction in inappropriate acid suppressant use via pharmacist oversight in surgery.

Key Research Challenges

Polypharmacy in Geriatrics

Older patients face heightened adverse events from pharmacokinetic changes and multiple drugs, with Japanese database analysis showing increased risks (Abe et al., 2017, 42 citations). Interventions reduced problems but require tailored monitoring (Hailu et al., 2020). Scaling to diverse populations remains difficult.

Dose Errors in Special Populations

HIV and oncology patients experience >20% error rates from contraindicated combinations and dosing issues (Carcelero et al., 2011; Kohler et al., 2002). Pharmacist training mitigates but real-time adjustments challenge busy wards. Variable patient physiology complicates standardization.

Pharmacist Intervention Scalability

Multidisciplinary models improve adherence but demand service design for broad adoption (Han et al., 2018). Education gaps persist, as in China's clinical pharmacy development (Hu et al., 2014). Economic barriers limit clinic expansion (Yamada & Nabeshima, 2015).

Essential Papers

ASHP Guidelines on Preventing Medication Errors with Antineoplastic Agents

David Köhler, Michael Montello, Barry R. Goldspiel et al. · 2002 · American Journal of Health-System Pharmacy · 120 citations

Journal Article ASHP Guidelines on Preventing Medication Errors with Antineoplastic Agents Get access David R. Kohler, Pharm.D., David R. Kohler, Pharm.D. Search for other works by this author on: ...

Drug related problems in admitted geriatric patients: the impact of clinical pharmacist interventions

Berhane Yohannes Hailu, Derebew Fikadu Berhe, Esayas Kebede Gudina et al. · 2020 · BMC Geriatrics · 113 citations

Abstract Background Geriatric patients are at high risk of Drug Related Problems (DRPs) due to multi- morbidity associated polypharmacy, age related physiologic changes, pharmacokinetic and pharmac...

Development and Current Status of Clinical Pharmacy Education in China

Ming Hu, Gary C. Yee, Naitong Zhou et al. · 2014 · American Journal of Pharmaceutical Education · 58 citations

Evaluation of antiretroviral-related errors and interventions by the clinical pharmacist in hospitalized HIV-infected patients

Esther Carcelero, Montserrat Tuset, M. Martin et al. · 2011 · HIV Medicine · 57 citations

Antiretroviral-related errors affected more than one-in-five patients. The most common causes of error were contraindicated or not recommended drug-drug combinations and dose-related errors. A clin...

Comparing Effectiveness of High-Fidelity Human Patient Simulation vs Case-Based Learning in Pharmacy Education

Ken Lee Chin, Yen Ling Yap, Wee Leng Lee et al. · 2014 · American Journal of Pharmaceutical Education · 48 citations

Safeguarding Older Adults From Inappropriate Over-the-Counter Medications: The Role of Community Pharmacists

Michelle A. Chui, Jamie A. Stone, Beth A. Martin et al. · 2013 · The Gerontologist · 46 citations

Pharmacists can play a key role in assisting older adults to select and use OTC medications.

Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database

Junko Abe, Ryogo Umetsu, Hiroaki Uranishi et al. · 2017 · PLoS ONE · 42 citations

Population aging is a global phenomenon, and choosing appropriate medical care for the elderly is critical. Polypharmacy is suspected to increase the risk of adverse events (AEs) in older patients....

Reading Guide

Foundational Papers

Start with Kohler et al. (2002, 120 citations) for antineoplastic error guidelines, then Carcelero et al. (2011, 57 citations) for HIV dose interventions, as they establish core principles of pharmacist-led pharmacokinetic adjustments.

Recent Advances

Study Hailu et al. (2020, 113 citations) on geriatric DRPs and Han et al. (2018, 35 citations) on team care models for current intervention impacts.

Core Methods

Core techniques: real-time pharmacist interventions (Luo et al., 2017), polypharmacy risk analysis from databases (Abe et al., 2017), and service design for clinics (Han et al., 2018).

How PapersFlow Helps You Research Clinical Pharmacokinetics in Practice

Discover & Search

Research Agent uses searchPapers and citationGraph to map 120-citation ASHP guidelines (Kohler et al., 2002) connected to 50+ polypharmacy studies, then exaSearch uncovers geriatric interventions like Hailu et al. (2020); findSimilarPapers extends to HIV dosing errors from Carcelero et al. (2011).

Analyze & Verify

Analysis Agent applies readPaperContent to extract error rates from Carcelero et al. (2011), verifies intervention impacts with CoVe against Hailu et al. (2020) data, and runs PythonAnalysis for statistical comparison of polypharmacy risks (Abe et al., 2017) using pandas; GRADE grading scores evidence strength for geriatric dosing.

Synthesize & Write

Synthesis Agent detects gaps in scalable interventions beyond Han et al. (2018) models, flags contradictions in OTC safeguards (Chui et al., 2013); Writing Agent uses latexEditText for dose-adjustment protocols, latexSyncCitations for 10-paper reviews, latexCompile for reports, and exportMermaid for pharmacokinetic workflow diagrams.

Use Cases

"Analyze polypharmacy adverse event rates in geriatrics from recent studies"

Research Agent → searchPapers('geriatric polypharmacy pharmacokinetics') → Analysis Agent → runPythonAnalysis(pandas on Abe et al. 2017 data) → matplotlib plots of risk ratios output.

"Draft LaTeX guidelines for antineoplastic dose adjustments in oncology"

Synthesis Agent → gap detection on Kohler et al. 2002 → Writing Agent → latexEditText(protocol) → latexSyncCitations(10 papers) → latexCompile(PDF) output.

"Find code for pharmacokinetic simulation models in clinical pharmacy papers"

Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → validated simulation scripts for dose modeling output.

Automated Workflows

Deep Research workflow scans 50+ papers on clinical interventions, chaining searchPapers → citationGraph → GRADE grading for systematic review of polypharmacy risks (Hailu et al., 2020). DeepScan's 7-step analysis with CoVe verifies dose error stats from Carcelero et al. (2011) against guidelines. Theorizer generates hypotheses on pharmacist clinic scalability from Yamada & Nabeshima (2015).

Try Doxa for Clinical Pharmacokinetics in Practice Research

Frequently Asked Questions

What defines Clinical Pharmacokinetics in Practice?

It applies pharmacokinetic principles to individualize dosing and monitor therapy in patients, focusing on adjustments for age, polypharmacy, and disease states (Kohler et al., 2002; Hailu et al., 2020).

What are common methods in this subtopic?

Methods include therapeutic drug monitoring, pharmacist interventions for dose errors, and multidisciplinary team care models to resolve drug-related problems (Carcelero et al., 2011; Han et al., 2018).

What are key papers?

Foundational: Kohler et al. (2002, 120 citations) on antineoplastic errors; Carcelero et al. (2011, 57 citations) on HIV interventions. Recent: Hailu et al. (2020, 113 citations) on geriatric DRPs.

What are open problems?

Challenges include scaling interventions for polypharmacy AEs (Abe et al., 2017) and standardizing education for global practice (Hu et al., 2014; Yamada & Nabeshima, 2015).